0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......

Journal Articles

in Colorectal Cancer
 41-60 of 138 Articles
From the Centers for Disease Control and Prevention |  FREE
JAMA. 2011;306(7):701-703. doi:.

Review | 
James J. Biagi, MD; Michael J. Raphael; William J. Mackillop, MB, ChB; et al.
JAMA. 2011;305(22):2335-2342. doi:10.1001/jama.2011.749.
Includes: CME, Supplemental Content

Editorial | 
Patrick M. M. Bossuyt, PhD
JAMA. 2011;305(21):2229-2230. doi:10.1001/jama.2011.729.

Medical News & Perspectives | 
Joan Stephenson, PhD
JAMA. 2011;305(20):2053-2054. doi:10.1001/jama.2011.685.

Original Contribution |  FREE
Teppei Morikawa, MD, PhD; Aya Kuchiba, PhD; Mai Yamauchi, PhD; et al.
JAMA. 2011;305(16):1685-1694. doi:10.1001/jama.2011.513.
Includes: Supplemental Content

Lab Reports | 
M. J. Friedrich
JAMA. 2011;305(1):28. doi:10.1001/jama.2010.1902.

Original Contribution |  FREE
Hermann Brenner, MD, MPH; Sha Tao, MSc; Ulrike Haug, PhD
JAMA. 2010;304(22):2513-2520. doi:10.1001/jama.2010.1773.

Medical News & Perspectives | 
Anita Slomski
JAMA. 2010;303(14):1356-1357. doi:10.1001/jama.2010.360.

Original Contribution |  FREE
Katherine L. Kahn, MD; John L. Adams, PhD; Jane C. Weeks, MD, MSc; et al.
JAMA. 2010;303(11):1037-1045. doi:10.1001/jama.2010.272.
Includes: Supplemental Content

Review | 
Susanna C. Larsson, PhD; Nicola Orsini, PhD; Alicja Wolk, DMSc
JAMA. 2010;303(11):1077-1083. doi:10.1001/jama.2010.263.
Includes: CME

Commentary | 
Hemant K. Roy, MD; Laura K. Bianchi, MD
JAMA. 2009;302(15):1696-1697. doi:10.1001/jama.2009.1499.

Commentary | 
Robert H. Brook, MD, ScD
JAMA. 2009;302(13):1465-1466. doi:10.1001/jama.2009.1427.

Editorial | 
Alfred I. Neugut, MD, PhD
JAMA. 2009;302(6):688-689. doi:10.1001/jama.2009.1145.

Original Contribution |  FREE
Andrew T. Chan, MD, MPH; Shuji Ogino, MD, PhD; Charles S. Fuchs, MD, MPH
JAMA. 2009;302(6):649-658. doi:10.1001/jama.2009.1112.

Clinical Crossroads Update | 
Anna A. Mattson-DiCecca, BA; Eileen Reynolds, MD
JAMA. 2009;302(6):678. doi:10.1001/jama.2009.1148.

Editorial | 
Emily Finlayson, MD, MS
JAMA. 2009;301(23):2498-2499. doi:10.1001/jama.2009.864.

Original Contribution |  FREE
Daniele Regge, MD; Cristiana Laudi, MD; Giovanni Galatola, MD; et al.
JAMA. 2009;301(23):2453-2461. doi:10.1001/jama.2009.832.

Preliminary Communication |  FREE
Scott A. Waldman, MD, PhD; Terry Hyslop, PhD; Stephanie Schulz, PhD; et al.
JAMA. 2009;301(7):745-752. doi:10.1001/jama.2009.141.
Includes: Supplemental Content

JAMA Patient Page |  FREE
John L. Zeller, MD, PhD; Cassio Lynm, MA; Richard M. Glass, MD
JAMA. 2008;300(23):2816. doi:10.1001/jama.300.23.2816.
Includes: Supplemental Content

Review | 
Edoardo Botteri, MSc; Simona Iodice, MSc; Vincenzo Bagnardi, PhD; et al.
JAMA. 2008;300(23):2765-2778. doi:10.1001/jama.2008.839.
Includes: Supplemental Content

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts
From The JAMA Network
JAMA Oncology
Editorial  | 
AREG and EREG as Predictive Biomarkers for RAS Wild-Type Colorectal Cancer Treated With Panitumumab A Fresh Approach to an Old Puzzle
Elizabeth C. Smyth, MB, BCh, MSc; Khurum Khan, MBBS; David Cunningham, FMedSci
JAMA Oncology
Original Investigation  | 
Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer
Jenny F. Seligmann, PhD; Faye Elliott, MSc; Susan D. Richman, PhD; et al.
JAMA Oncology
Invited Commentary  | 
Biomarkers of Fluorouracil Toxicity Insight From the PETACC-8 Trial
Steven M. Offer, PhD; Robert B. Diasio, MD
JAMA Oncology
Original Investigation  | 
DPYD Genotyping to Predict Adverse Events Following Treatment With Flourouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer A Secondary Analysis of the PETACC-8 Randomized Clinical Trial
Valérie Boige, MD, PhD; Marc Vincent, PhD; Philippe Alexandre, MS; et al.